Table 2 Mean, median, and 5 year overall and disease specific NHL survival in Tyrol 1991–2000.
| NHL entity | Disease specific survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| Median (months) | Mean (months) | Relative* | Median (months) | Mean (months) | Relative* | |
| Marginal zone lymphoma of MALT | Not reached | 115 | 88% | 128 | 98 | 78% |
| Follicular lymphoma | Not reached | 105 | 80% | Not reached | 98 | 75% |
| B lymphoblastic leukaemia/lymphoma | Not reached | 88 | 74% | Not reached | 77 | 63% |
| T cell rich B cell lymphoma | Not reached | 62 | 71% | 83 | 62 | 71% |
| Hairy cell leukaemia | Not reached | 111 | 69% | Not reached | 92 | 73% |
| Burkitt lymphoma/leukaemia | Not reached | 82 | 69% | Not reached | 82 | 69% |
| Anaplastic large cell lymphoma | 87 | 68 | 69% | 55 | 57 | 49% |
| B chronic lymphocytic leukaemia | 105 | 90 | 65% | 79 | 73 | 57% |
| Extranodal diffuse large B cell lymphoma | Not reached | 84 | 65% | 60 | 66 | 50% |
| T lymphoblastic leukaemia/lymphoma | Not reached | 83 | 63% | 16 | 63 | 45% |
| Mediastinal diffuse large B cell lymphoma | 18 | 54 | 47% | 18 | 54 | 47% |
| Nodal diffuse large B cell lymphoma | 31 | 59 | 42% | 22 | 41 | 25% |
| Mature T/NK NHLs | 17 | 51 | 36% | 14 | 37 | 25% |
| Multiple myeloma | 33 | 54 | 35% | 24 | 43 | 26% |
| Diffuse large B cell lymphoma of CNS | 14 | 29 | 24% | 9 | 25 | 18% |
| Mantle cell lymphoma | 23 | 44 | 20% | 22 | 42 | 19% |
Mean follow up was 42 months (median, 32; range, 1–132).
*Relative 5 year survival.
CNS, central nervous system; MALT, mucosa associated lymphoid tissue; NHL, non‐Hodgkin lymphoma; NK, natural killer cell.